What did the American Cancer Society report say about cancer survival rates?

The American Cancer Society reported that seven in 10 people now survive five years or more after a cancer diagnosis.

Why are cancer mortality rates declining in the US?

Cancer mortality rates are declining due to smoking reductions, earlier detection, and improved treatments supported by research.

What threats could reverse cancer survival progress according to the ACS?

The ACS warns that persistent disparities and potential cuts to federal research funding could reverse progress.

Home / Health / Cancer Survival Soars, But Gaps Persist

Cancer Survival Soars, But Gaps Persist

14 Jan

•

Summary

Seven in 10 people now survive five years or more after diagnosis.
Cancer mortality rates declined through 2023, averting millions of deaths.
Disparities and funding threats may reverse cancer survival progress.

Survival rates for cancer in the United States have shown remarkable improvement, with a recent report indicating that seven out of ten individuals now survive for five years or more following their diagnosis. This significant increase, up from only half in the mid-1970s, is largely attributed to decades of dedicated cancer research, leading to more effective treatments that often transform deadly diagnoses into manageable chronic conditions.

The overall decline in cancer mortality rates, which continued through 2023, has averted an estimated 4.8 million deaths since 1991. Key factors contributing to this success include reduced smoking rates, earlier detection methods, and advancements in treatment protocols. Notable improvements are seen in survival rates for aggressive cancers like myeloma, liver, and lung cancer.

Despite these positive trends, challenges remain. Incidence rates for common cancers such as breast and prostate continue to rise, and lung cancer is projected to be the leading cause of cancer death by 2026. Furthermore, existing socioeconomic, racial, and ethnic disparities, coupled with potential federal funding cuts for research, pose a significant threat to future progress and could reverse hard-won gains.